Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact.

Coursey TG, Chen PW, Niederkorn JY.

J Leukoc Biol. 2012 Nov;92(5):939-50. doi: 10.1189/jlb.0312122. Epub 2012 Jun 12.

2.

CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

Dace DS, Chen PW, Niederkorn JY.

Immunology. 2008 Mar;123(3):367-77. Epub 2007 Oct 17.

3.

Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.

Dace DS, Chen PW, Alizadeh H, Niederkorn JY.

J Leukoc Biol. 2007 Feb;81(2):421-9. Epub 2006 Oct 31.

PMID:
17077163
4.

Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.

Coursey TG, Chen PW, Niederkorn JY.

Cancer Res. 2011 Apr 1;71(7):2445-54. doi: 10.1158/0008-5472.CAN-10-2628. Epub 2011 Feb 9.

5.

IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.

Coursey TG, Chen PW, Niederkorn JY.

J Immunol. 2011 Oct 15;187(8):4219-28. doi: 10.4049/jimmunol.1100826. Epub 2011 Sep 14.

6.
7.

Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.

Wang S, Boonman ZF, Li HC, He Y, Jager MJ, Toes RE, Niederkorn JY.

J Immunol. 2003 Sep 15;171(6):2789-96.

8.

Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.

Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY.

J Immunol. 1987 Jun 15;138(12):4515-23.

PMID:
3108394
9.

Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.

Miller MR, Mandell JB, Beatty KM, Harvey SA, Rizzo MJ, Previte DM, Thorne SH, McKenna KC.

Cancer Immunol Res. 2014 Dec;2(12):1175-85. doi: 10.1158/2326-6066.CIR-14-0093-T. Epub 2014 Sep 23.

10.

Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.

Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2001 Nov 15;167(10):5832-7.

11.

Natural Killer T Cells Contribute to Neutrophil Recruitment and Ocular Tissue Damage in a Model of Intraocular Tumor Rejection.

Ligocki AJ, Niederkorn JY.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):813-23. doi: 10.1167/iovs.15-18786.

12.

Macrophages are vital in spontaneous intraocular tumor eradication.

Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ.

Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2959-65.

PMID:
16799039
13.

Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.

Knisely TL, Niederkorn JY.

Invest Ophthalmol Vis Sci. 1990 Feb;31(2):247-57.

PMID:
2154414
14.

Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.

Chen PW, Uno T, Ksander BR.

Exp Eye Res. 2006 Sep;83(3):574-83. Epub 2006 Apr 27.

PMID:
16643898
15.

Histopathologic analysis of intraocular allogeneic tumors in mice.

Luckenbach MW, Streilein JW, Niederkorn JY.

Invest Ophthalmol Vis Sci. 1985 Oct;26(10):1368-76.

PMID:
3930419
16.

Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.

Ligocki AJ, Brown JR, Niederkorn JY.

J Leukoc Biol. 2016 May;99(5):735-47. doi: 10.1189/jlb.3A0315-093RRR. Epub 2015 Nov 17.

17.

Innate IFN-γ promotes development of experimental autoimmune encephalomyelitis: a role for NK cells and M1 macrophages.

Dungan LS, McGuinness NC, Boon L, Lynch MA, Mills KH.

Eur J Immunol. 2014 Oct;44(10):2903-17. doi: 10.1002/eji.201444612. Epub 2014 Aug 19.

18.

Successful immunotherapy of an intraocular tumor in mice.

Schurmans LR, den Boer AT, Diehl L, van der Voort EI, Kast WM, Melief CJ, Toes RE, Jager MJ.

Cancer Res. 1999 Oct 15;59(20):5250-4.

19.
20.

Supplemental Content

Support Center